Published in Adv Funct Mater on June 01, 2015
The Fate of the Tumor in the Hands of Microenvironment: Role of TAMs and mTOR Pathway. Mediators Inflamm (2016) 0.82
Delivery strategies and potential targets for siRNA in major cancer types. Adv Drug Deliv Rev (2016) 0.82
Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy. J Nanobiotechnology (2017) 0.78
Gold Nanobeacons for Tracking Gene Silencing in Zebrafish. Nanomaterials (Basel) (2017) 0.76
Gold Nanotheranostics: Proof-of-Concept or Clinical Tool? Nanomaterials (Basel) (2015) 0.76
Multifunctional nanoparticles for cancer immunotherapy. Hum Vaccin Immunother (2016) 0.76
Nanoparticle Design Strategies for Effective Cancer Immunotherapy. J Biomed (Syd) (2017) 0.75
Programmable biomaterials for dynamic and responsive drug delivery. Exp Biol Med (Maywood) (2016) 0.75
Emerging nanotechnologies for cancer immunotherapy. Exp Biol Med (Maywood) (2016) 0.75
Biodegradable poly (lactic acid-co-glycolic acid) scaffolds as carriers for genetically-modified fibroblasts. PLoS One (2017) 0.75
TIPS Pentacene Loaded PEO-PDLLA Core-Shell Nanoparticles have Similar Cellular Uptake Dynamics in M1 and M2 Macrophages and In Corresponding In Vivo Microenvironments. Nanomedicine (2016) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81
Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer (2004) 14.55
Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov (2009) 12.46
Cancer and the chemokine network. Nat Rev Cancer (2004) 10.27
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
Microenvironmental regulation of tumor progression and metastasis. Nat Med (2013) 8.37
Monocyte recruitment during infection and inflammation. Nat Rev Immunol (2011) 7.55
Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature (2008) 7.10
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol (2005) 5.99
VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment. J Clin Invest (2004) 5.59
Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol (2011) 3.95
Delivery materials for siRNA therapeutics. Nat Mater (2013) 3.70
Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials (2008) 3.68
Current prospects for RNA interference-based therapies. Nat Rev Genet (2011) 3.63
Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol (2012) 3.48
Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature (2014) 3.31
Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res (2007) 3.03
Tumor progression and metastasis. Carcinogenesis (2000) 2.57
Critical role of CD11b+ macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance, and inflammation resolution. Blood (2009) 2.30
In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat Nanotechnol (2014) 2.24
Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol (2004) 2.05
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation. Proc Natl Acad Sci U S A (2012) 1.90
Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res (2010) 1.60
Anti-tumour strategies aiming to target tumour-associated macrophages. Immunology (2013) 1.40
Tumor-associated macrophages: function, phenotype, and link to prognosis in human lung cancer. Am J Transl Res (2012) 1.37
Small silencing RNAs: state-of-the-art. Adv Drug Deliv Rev (2009) 1.34
Gene silencing by gold nanoshell-mediated delivery and laser-triggered release of antisense oligonucleotide and siRNA. ACS Nano (2012) 1.30
Silencing or stimulation? siRNA delivery and the immune system. Annu Rev Chem Biomol Eng (2011) 1.23
Tumour-associated macrophages and cancer. Curr Opin Pharmacol (2013) 1.20
Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proc Natl Acad Sci U S A (2010) 1.20
Targeted delivery of proapoptotic peptides to tumor-associated macrophages improves survival. Proc Natl Acad Sci U S A (2013) 1.16
Design of multifunctional gold nanoparticles for in vitro and in vivo gene silencing. ACS Nano (2012) 1.10
Gold-nanobeacons for simultaneous gene specific silencing and intracellular tracking of the silencing events. Biomaterials (2013) 1.00
Antibody-drug gold nanoantennas with Raman spectroscopic fingerprints for in vivo tumour theranostics. J Control Release (2014) 1.00
Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol Pharm (2013) 0.98
In vivo tumor targeting via nanoparticle-mediated therapeutic siRNA coupled to inflammatory response in lung cancer mouse models. Biomaterials (2013) 0.95
Target-responsive DNA/RNA nanomaterials for microRNA sensing and inhibition: the jack-of-all-trades in cancer nanotheranostics? Adv Drug Deliv Rev (2014) 0.95
Suppression of nanoparticle cytotoxicity approaching in vivo serum concentrations: limitations of in vitro testing for nanosafety. Nanoscale (2014) 0.93
Bronchoalveolar lavage cell pattern from healthy human lung. Clin Exp Immunol (2012) 0.92
CD163 expression was associated with angiogenesis and shortened survival in patients with uniformly treated classical Hodgkin lymphoma. PLoS One (2014) 0.82
The density of macrophages in colorectal cancer is inversely correlated to TGF-β1 expression and patients' survival. J Mol Histol (2013) 0.81